|
Mar 20
|
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
|
|
Mar 14
|
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
|
|
Mar 8
|
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
|
|
Mar 6
|
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
|
|
Mar 5
|
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
|
|
Dec 18
|
ACHV: Not So Fast…
|
|
May 25
|
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
|
|
May 25
|
ACHV: ORCA-3 Topline
|
|
May 24
|
Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) Shift From Loss To Profit
|
|
May 23
|
Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial
|
|
May 23
|
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
|